Posts
Diabetic retinopathy is
a diabetes complication that affects eyes. It is caused by damage to
the blood vessels of the light-sensitive tissue of retina (the back of the eye).
Initially, diabetic retinopathy may cause no symptoms or only mild
vision problems. Diabetic retinopathy symptoms including impaired color vision,
blurred vision, fluctuating vision, or sometimes dark and empty areas in vision
leads to vision loss. However, the line of treatment depends entirely on the
patient’s disease condition, may require intraocular injections, laser surgery,
and vascular endothelial growth factor (VEFG) therapy.
The two phases of diabetic retinopathy are Proliferative
Diabetic Retinopathy and Non Proliferative Diabetic Retinopathy. It can be
treated through vitrectomy, medicines, and laser surgery. Moreover, it can
develop in any individual who is suffering from diabetes (type 1 or 2). In the
United States, diabetic retinopathy is the leading cause of blindness. Increasing
prevalence and incidence of diabetes around the world is key driving factor for
the diabetic
retinopathy market. The number of Americans with diabetic
retinopathy is expected to double, from 7.7 million to 14.6 million (from
2010 to 2050), according to the Centers for Disease Control and Prevention
(CDC).
Growing geriatric population and increasing
prevalence of obesity due to sedentary lifestyle is also expected to augment
the market growth. Moreover, factors such as rising awareness among diabetic
patients about the early detection of the disease, rise in healthcare
facilities, advanced technology, and the availability of numerous treatment
options are driving the market. However, lack of skilled professionals for the treatment
and negligence of diabetic retinopathy in emerging and developing countries is
restraining the growth of the market. In terms of geography, the diabetic
retinopathy market is divided into six regions, such as North America, Asia
Pacific, Europe, South America, the Middle East, and Africa.
Asia Pacific is expected to witness substantial
growth in the market due to the increasing prevalence diabetes in the region. According
to the International Diabetes Federation, India is home to 77 million
diabetics, which is the second highest in the world. China leads the list with
over 116 million diabetics. Moreover, increasing approvals and launches of new diabetic
retinopathy medications are also expected to drive the market growth. For
instance, in 2019, Regeneron Pharmaceutical received FDA approval for EYLEA, an
aflibercept injection for diabetes retinopathy. However, EYLEA is the only VEFG
inhibitor approved for diabetes retinopathy in two dosing options.
No comments:
Post a Comment